Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model.

Authors: Bhattacharjee, PS  Neumann, DM  Foster, TP  Clement, C  Singh, G  Thompson, HW  Kaufman, HE  Hill, JM 
Citation: Bhattacharjee PS, etal., Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4263-8. doi: 10.1167/iovs.08-2077. Epub 2008 May 30.
Pubmed: (View Article at PubMed) PMID:18515564
DOI: Full-text: DOI:10.1167/iovs.08-2077

PURPOSE: To evaluate efficacy of the small apolipoprotein E (apoE) mimetic dimer peptide (apoEdp) in the treatment of herpetic stromal keratitis in a mouse ocular model and determine its therapeutic effects against HSV-1-induced inflammatory cytokines. METHODS: Female C57Bl/6 mice were corneally infected with HSV-1 strain KOS-GFP; topical treatment was initiated 24 hours after infection and continued for 10 consecutive days. Treatment groups were 1% apoEdp, 1% trifluorothymidine (TFT), and phosphate-buffered saline (PBS). The incidence and severity of stromal keratitis were monitored by slit lamp examination in a masked fashion. Infectious HSV-1 titer in eye swabs and alteration in inflammatory cytokines were determined in the early postinfection period by real-time RT-PCR. RESULTS: One percent apoEdp treatment, which significantly reduced the incidence and severity of HSK, was equal to the effect of 1% TFT; both groups had significantly lower incidence and severity than the placebo treatment group. The in vivo mouse ocular model results of apoEdp therapy correlated with accelerated clearance of virus from eye swabs. Topical 1% apoEdp treatment in mice significantly downregulated gene expression of mouse proinflammatory cytokines. CONCLUSIONS: These results suggest that topical treatment with apoE peptide has efficacy against HSK through anti-HSV-1 and anti-inflammatory activities.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 7771550
Created: 2013-12-19
Species: All species
Last Modified: 2013-12-19
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.